Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP).

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Immunology

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clim.2017.12.010PMID 29287794
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Investigation of platelet apoptosis in adult patients with chronic immune thrombocytopenia

  2017cited by this paper
• Serum vitamin D levels in children with newly diagnosed and chronic immune thrombocytopenia.

  2016cited by this paper
• Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray‐based serum protein profiling

  2016cited by this paper
• Decreased immunosuppressive actions of 1α, 25-dihydroxyvitamin D3 in patients with immune thrombocytopenia.

  2016cited by this paper
• Oxidative Stress Is Predominant in Female but Not in Male Patients with Autoimmune Thrombocytopenia

  2014cited by this paper
• Platelet Apoptosis in Adult Immune Thrombocytopenia. Relationship with Auto-Antibodies, Platelet Function and Treatment

  2014cited by this paper
• The BAFF/APRIL system in SLE pathogenesis

  2014cited by this paper
• [Expression and significance of vitamin D and its receptor mRNA in the peripheral blood of initial immune thrombocytopenic patients].

  2013cited by this paper
• Immune thrombocytopenia and B-cell-activating factor/a proliferation-inducing ligand.

  2013cited by this paper
• Antioxidant Status and Oxidative Stress in Patients with Chronic ITP

  2013cited by this paper
• B cell activating factor in obesity is regulated by oxidative stress in adipocytes

  2013cited by this paper
• Bone mass and biochemical markers of bone turnover in children and adolescents with chronic immune thrombocytopenia: Relation to corticosteroid therapy and vitamin D receptor gene polymorphisms

  2013cited by this paper
• B-cell targeted therapeutics in clinical development

  2013cited by this paper
• Defective regulatory B-cell compartment in patients with immune thrombocytopenia.

  2012cited by this paper
• Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin

  2012cited by this paper
• Solar Radiation and Vitamin D: Mitigating Environmental Factors in Autoimmune Disease

  2012cited by this paper
• Reduced antioxidant capacities in platelets from patients with autoimmune thrombocytopenia purpura (ITP)

  2012cited by this paper
• The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

  2011cited by this paper
• Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL.

  2011cited by this paper
• The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP.

  2011cited by this paper
• Oxidative stress may cause ITP.

  2011cited by this paper
• ITP: tolerance lost.

  2011cited by this paper
• Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.

  2011cited by this paper
• Immune thrombocytopenia.

  2010cited by this paper
• REVIEW Glucocorticoids

  2010cited by this paper
• Mitochondrial Localization of Vitamin D Receptor in Human Platelets and Differentiated Megakaryocytes

  2010cited by this paper
• “APRIL hath put a spring of youth in everything”: Relevance of APRIL for survival

  2009cited by this paper
• The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis

  2009cited by this paper
• Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications

  2009cited by this paper
• BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura

  2009cited by this paper
• Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus

  2008cited by this paper
• Correction of Th1-dominant Cytokine Profiles by High-dose Dexamethasone in Patients with Chronic Idiopathic Thrombocytopenic Purpura

  2007cited by this paper
• High‐level serum B‐cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura

  2007cited by this paper
• An APRIL to remember: novel TNF ligands as therapeutic targets

  2006cited by this paper
• Reactive oxygen species augment B-cell-activating factor expression.

  2006cited by this paper
• Interleukin 4, interleukin 6 and interleukin 10 polymorphisms in children with acute and chronic immune thrombocytopenic purpura

  2005cited by this paper
• BAFF Overexpression Is Associated with Autoantibody Production in Autoimmune Diseases

  2005cited by this paper
• The BAFF/APRIL system: an important player in systemic rheumatic diseases.

  2005cited by this paper
• Association Between Circulating Levels of the Novel TNF Family Members APRIL and BAFF and Lymphoid Organization in Primary Sjögren’s Syndrome

  2005cited by this paper
• Raised serum APRIL levels in patients with systemic lupus erythematosus

  2004cited by this paper
• Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura

  2004cited by this paper
• Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis.

  2004cited by this paper
• The sympathetic nervous system is involved in variant Creutzfeldt-Jakob disease

  2003cited by this paper
• Antiplatelet Antibodies in Chronic Adult Immune Thrombocytopenic Purpura: Assays and Epitopes

  2003cited by this paper
• DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

  2002cited by this paper
• APRIL modulates B and T cell immunity.

  2002cited by this paper
• Levels of malondialdehyde, glutathione and ascorbic acid in idiopathic thrombocytopaenic purpura.

  2002cited by this paper
• Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.

  2000cited by this paper
• Cytokines and the regulation of tolerance.

  2000cited by this paper
• BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

  1999cited by this paper
• APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth

  1998cited by this paper
• Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells.

  1996cited by this paper
• Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells

  1996cited by this paper
• Self-peptides in the initiation of lupus autoimmunity.

  1995cited by this paper
• H2O2 and antioxidants have opposite effects on activation of NF‐kappa B and AP‐1 in intact cells: AP‐1 as secondary antioxidant‐responsive factor.

  1993cited by this paper
• Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line.

  1992cited by this paper
• Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF‐kappa B transcription factor and HIV‐1.

  1991cited by this paper
• Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex

  1990cited by this paper
• Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.

  1987cited by this paper
• Idiopathic thrombocytopenic purpura with defective oxidative metabolism of neutrophils.

  1984cited by this paper
• Immune thrombocytopenia. Use of a Coombs antiglobulin test to detect IgG and C3 on platelets.

  1979cited by this paper
• Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.

  1951cited by this paper

• Immune thrombocytopenia in patients with connective tissue disease

  2026cites this paper
• BLySfully BAFFled: The Expanding Immune Thrombocytopenia Armamentarium

  2025cites this paper
• Evans syndrome revisited.

  2025cites this paper
• The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments.

  2025cites this paper
• Successful treatment of refractory systemic lupus erythematosus-associated immune thrombocytopenia with drug-induced liver injury with telitacicept: a case report and review

  2025cites this paper
• Immunomodulatory Mechanisms and Therapeutic Potential of Vitamin D in Immune Thrombocytopenia

  2025cites this paper
• Glucocorticoid Resistance in Immune Thrombocytopenia: A Therapeutic Challenge or a Window for Precision Medicine?

  2025cites this paper
• Traditional and Novel Treatments for Systemic Lupus Erythematosus

  2024cites this paper
• A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults

  2024cites this paper
• Forging the Future: B Cell Activating Factor’s Impact on Nephrotic Syndrome

  2024cites this paper
• Immune thrombocytopenia: a review of pathogenesis and current treatment

  2024cites this paper
• The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study

  2024cites this paper
• 2025 update on clinical trials in immune thrombocytopenia

  2024cites this paper
• BAFF sérico como marcador en el tratamiento glucocorticoide del lupus eritematoso sistémico

  2023cites this paper
• Dynamic interplay between corticosteroid treatment and the role of SRC-1 gene dysregulation in the progression of WHO-Grade 4 Astrocytoma

  2023cites this paper
• Predicting systemic lupus erithematosus disease activity index 2000 (Sledai 2k) score after pulse dose metyl prednisolone in severe systemic lupus erithematosus

  2023cites this paper
• BAFF as a predictive marker for treatment response in immune thrombocytopenia patients

  2023cites this paper
• B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis

  2022cites this paper
• Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment.

  2022cites this paper
• Increased let-7b-5p is associated with enhanced BAFF-R expression and B cell survival in immune thrombocytopenia.

  2021cites this paper
• B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders

  2021cites this paper
• Cellular immune dysregulation in the pathogenesis of immune thrombocytopenia.

  2020cites this paper
• The role of BAFF and APRIL in rheumatoid arthritis

  2019cites this paper
• Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia

  2018cites this paper
• ÉTUDE DES CELLULES LYMPHOÏDES INNÉES SPLÉNIQUES HUMAINES ET DE LEURS IMPLICATIONS AU COURS DE LA THROMBOPÉNIE IMMUNOLOGIQUE

  2018cites this paper